Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker ASND · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in Achondr… NCT07924059 · Achondroplasia Dual therapy with navepegritide and lonapegsomatropin, Dual… | ASND Ascendis Pharma A/S | Phase 3 | Not yet recruiting | 144 | Sep 2028 | Registry ↗ |
| Nov 5, 2026 | Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropi… NCT07221851 · Turner Syndrome, Short Stature Homeobox Gene Mutation Lonapegsomatropin [SKYTROFA®], Somatropin Pen Injector | ASND Ascendis Pharma A/S | Phase 3 | Recruiting | 186 | Feb 2028 | Registry ↗ |
| Nov 4, 2026 | A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide Versus Placebo in Children and Ad… NCT07917143 · Hypochondroplasia Navepegritide, Placebo for Navepegritide | ASND Ascendis Pharma A/S | Phase 3 | Not yet recruiting | 81 | Oct 2028 | Registry ↗ |
| Oct 13, 2026 | A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of… NCT06732895 · Achondroplasia Navepegritide, Placebo for navepegritide | ASND Ascendis Pharma A/S | Phase 2 | Active, not recruiting | 25 | Sep 2027 | Registry ↗ |
| Aug 7, 2026 | A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring Y… NCT07264634 · Hypoparathyroidism Palopegteriparatide | ASND Ascendis Pharma A/S | — | Recruiting | 10 | Aug 2027 | Registry ↗ |
| Jul 28, 2026 | A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypopar… NCT07706764 · Hypoparathyroidism Palopegteriparatide | ASND Ascendis Pharma A/S | Phase 3 | Recruiting | 12 | Aug 2027 | Registry ↗ |
| Jul 8, 2026 | Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH i… NCT01947907 · Growth Hormone Deficiency (GHD) ACP-001, Human Growth Hormone | ASND Ascendis Pharma A/S | Phase 2 | Completed | 53 | Jul 2015 | Registry ↗ |
| Jul 8, 2026 | A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) in Adults With Growth… NCT01247675 · Adult Growth Hormone Deficiency ACP-001 (TransCon hGH), ACP-001 (TransCon hGH) | ASND Ascendis Pharma A/S | Phase 2 | Completed | 37 | May 2011 | Registry ↗ |
| Jul 7, 2026 | A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone… NCT03344458 · Growth Hormone Deficiency, Pediatric, Endocrine System Dise… TransCon hGH | ASND Ascendis Pharma A/S | Phase 3 | Completed | 298 | Feb 21, 2023 | Registry ↗ |
| Jul 2, 2026 | A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administe… NCT04085523 · Achondroplasia TransCon CNP, Placebo for TransCon CNP | ASND Ascendis Pharma A/S | Phase 2 | Completed | 57 | Sep 27, 2022 | Registry ↗ |
| Jun 18, 2026 | A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypopara… NCT04009291 · Hypoparathyroidism, Endocrine System Diseases TransCon PTH, Placebo for TransCon PTH | ASND Ascendis Pharma A/S | Phase 2 | Completed | 59 | Mar 6, 2020 | Registry ↗ |
| Apr 8, 2026 | A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (… NCT06079398 · Achondroplasia Navepegritide, Placebo for Navepegritide | ASND Ascendis Pharma A/S | Phase 2 | Recruiting | 72 | Dec 2027 | Registry ↗ |
| Mar 2, 2026 | A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YO… NCT07345494 · Hypoparathyroidism Palopegteriparatide | ASND Ascendis Pharma A/S | — | Recruiting | 50 | Jan 2036 | Registry ↗ |
| Aug 1, 2025 | TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Nec… NCT05980598 · Head and Neck Neoplasms TransCon TLR7/8 Agonist, Pembrolizumab | ASND Ascendis Pharma A/S | Phase 2 | Terminated | 27 | Mar 28, 2025 | Registry ↗ |
| Mar 19, 2024 | A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia NCT03875534 · Achondroplasia | ASND Ascendis Pharma A/S | — | Completed | 260 | Jan 12, 2024 | Registry ↗ |
| Jan 14, 2019 | A Safety, Tolerability and Pharmacokinetics Study of TransCon Treprostinil in Healthy Adult Male Vo… NCT03803163 · Healthy Volunteers TransCon Treprostinil | ASND Ascendis Pharma A/S | Phase 1 | Terminated | 20 | Jun 2015 | Registry ↗ |
16 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 4:10 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances